Elvin Kedhi1, Mark W Kennedy1, Akiko Maehara2, Alexandra J Lansky3, Thomas C McAndrew4, Steven P Marso5, Bernard De Bruyne6, Patrick W Serruys7, Gregg W Stone8. 1. Isala Klinieken, Zwolle, the Netherlands. 2. New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York; Cardiovascular Research Foundation, New York, New York. 3. Yale Medical Center, New Haven, Connecticut. 4. Cardiovascular Research Foundation, New York, New York. 5. Mid America Heart Institute, St. Luke's Hospital, Kansas City, Missouri. 6. Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium. 7. Erasmus University, Thoraxcentrum, Rotterdam, the Netherlands. 8. New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York; Cardiovascular Research Foundation, New York, New York. Electronic address: gs2184@columbia.edu.
Abstract
OBJECTIVES: This study sought to investigate the relationship between thin-cap fibroatheromas (TCFAs) on major adverse cardiac events (MACEs) arising from medically treated nonculprit lesions (NCLs) in patients with acute coronary syndromes (ACS) with and without diabetes mellitus (DM). BACKGROUND: MACEs occur frequently in patients with DM and ACS. The impact of plaque composition on subsequent MACEs in DM patients with ACS is unknown. METHODS: In the PROSPECT (Providing Regional Observations Study Predictors of Events in the Coronary Tree) study, using 3-vessel radiofrequency intravascular ultrasound, we analyzed the incidence of NCL-MACE in 2 propensity-matched groups according to the presence of DM and TCFA. RESULTS: Among 697 patients, 119 (17.7%) had DM. The 3-year total MACE rate (29.4% vs. 18.8%; p = 0.01) was significantly higher in patients with versus without DM, driven by a higher rate of NCL-MACE in DM (18.7% vs. 10.4%; p = 0.02). Propensity score matching generated 2 balanced groups with and without DM of 82 patients each. Among DM patients, the presence of ≥1 TCFA was associated with higher NCL-MACE at 3 years (27.8% vs. 8.9% in patients without a TCFA, hazard ratio: 3.56; 95% confidence interval: 0.98 to 12.96; p = 0.04). DM patients without a TCFA had a similar 3-year rate of NCL-MACE as patients without DM (8.9% vs. 8.9%; hazard ratio: 1.09; 95% confidence interval: 0.27 to 4.41; p = 0.90). CONCLUSIONS: ACS patients with DM and ≥1 TCFA have a high rate of NCL-MACE at 3 years. In contrast, the prognosis of ACS patients with DM but no TCFAs is favorable and similar to patients without DM.
OBJECTIVES: This study sought to investigate the relationship between thin-cap fibroatheromas (TCFAs) on major adverse cardiac events (MACEs) arising from medically treated nonculprit lesions (NCLs) in patients with acute coronary syndromes (ACS) with and without diabetes mellitus (DM). BACKGROUND:MACEs occur frequently in patients with DM and ACS. The impact of plaque composition on subsequent MACEs in DMpatients with ACS is unknown. METHODS: In the PROSPECT (Providing Regional Observations Study Predictors of Events in the Coronary Tree) study, using 3-vessel radiofrequency intravascular ultrasound, we analyzed the incidence of NCL-MACE in 2 propensity-matched groups according to the presence of DM and TCFA. RESULTS: Among 697 patients, 119 (17.7%) had DM. The 3-year total MACE rate (29.4% vs. 18.8%; p = 0.01) was significantly higher in patients with versus without DM, driven by a higher rate of NCL-MACE in DM (18.7% vs. 10.4%; p = 0.02). Propensity score matching generated 2 balanced groups with and without DM of 82 patients each. Among DMpatients, the presence of ≥1 TCFA was associated with higher NCL-MACE at 3 years (27.8% vs. 8.9% in patients without a TCFA, hazard ratio: 3.56; 95% confidence interval: 0.98 to 12.96; p = 0.04). DMpatients without a TCFA had a similar 3-year rate of NCL-MACE as patients without DM (8.9% vs. 8.9%; hazard ratio: 1.09; 95% confidence interval: 0.27 to 4.41; p = 0.90). CONCLUSIONS: ACS patients with DM and ≥1 TCFA have a high rate of NCL-MACE at 3 years. In contrast, the prognosis of ACS patients with DM but no TCFAs is favorable and similar to patients without DM.
Authors: Mark W Kennedy; Eliza Kaplan; Rik S Hermanides; Enrico Fabris; Veemal Hemradj; Petra C Koopmans; Jan-Hank E Dambrink; A T Marcel Gosselink; Arnoud W J Van't Hof; Jan Paul Ottervanger; Vincent Roolvink; Wouter S Remkes; Aize van der Sluis; Harry Suryapranata; Elvin Kedhi Journal: Cardiovasc Diabetol Date: 2016-07-19 Impact factor: 9.951
Authors: Mark W Kennedy; Enrico Fabris; Alexander J Ijsselmuiden; Holger Nef; Sebastian Reith; Javier Escaned; Fernando Alfonso; Niels van Royen; Wojtek Wojakowski; Adam Witkowski; Ciro Indolfi; Jan Paul Ottervanger; Harry Suryapranata; Elvin Kedhi Journal: Cardiovasc Diabetol Date: 2016-10-10 Impact factor: 9.951
Authors: Hsin-I Teng; Hsiang-Yao Chen; Chuan-Tsai Tsai; Wei-Chieh Huang; Ying-Ying Chen; Chien-Hung Hsueh; William K Hau; Tse-Min Lu Journal: Front Cardiovasc Med Date: 2022-08-30
Authors: Mariusz Tomaniak; Dorota Ochijewicz; Łukasz Kołtowski; Adam Rdzanek; Arkadiusz Pietrasik; Jacek Jąkała; Magdalena Slezak; Krzysztof P Malinowski; Martyna Zaleska; Jakub Maksym; Piotr Barus; Tomasz Roleder; Krzysztof J Filipiak; Grzegorz Opolski; Janusz Kochman Journal: J Clin Med Date: 2021-05-28 Impact factor: 4.241
Authors: Tomas Kovarnik; Zhi Chen; Gary S Mintz; Andreas Wahle; Kristyna Bayerova; Ales Kral; Martin Chval; Karel Kopriva; John Lopez; Milan Sonka; Ales Linhart Journal: Cardiovasc Diabetol Date: 2017-12-07 Impact factor: 9.951
Authors: Shaoping Nie; Yongxiang Wei; Xiao Wang; Jingyao Fan; Yunhui Du; Changsheng Ma; Xinliang Ma Journal: BMJ Open Diabetes Res Care Date: 2019-12-18